Abstract |
For cervical cancer prevention, Cervarix(HPV-16/18)was approvedin Japan andvaccination programs against HPV-16/18 were startedin December, 2009. This vaccine is almost 100% effective in preventing high-grade precancer associated with the HPV types; it is safe and well tolerated. In Japan, universal vaccination of females between 11 and 14 years is recommended. We all look forward to eradicating cervical cancer in the not too distant future.
|
Authors | Hiroyuki Yoshikawa |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 37
Issue 6
Pg. 971-5
(Jun 2010)
ISSN: 0385-0684 [Print] Japan |
PMID | 20567096
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Cancer Vaccines
- Papillomavirus Vaccines
- human papillomavirus vaccine, L1 type 16, 18
|
Topics |
- Cancer Vaccines
(adverse effects, immunology)
- Clinical Trials as Topic
- Female
- Humans
- Papillomavirus Vaccines
(adverse effects, immunology)
- Uterine Cervical Neoplasms
(immunology, prevention & control)
- Vaccination
(trends)
|